Howson Pharmaceuticals went to Hong Kong to list, spirit, anti-tumor drugs in the domestic leading.

(Health Times network end reporter Zhao Mengmeng) Following the expiration of the form on September 6 last year, on April 11, Howson Pharmaceuticals submitted an IPO prospectus to the Hong Kong Stock Exchange for the second time, and the company intends to go public in Hong Kong.
is understood that Jiangsu Howson was founded in 1995, is one of the top research and development-driven pharmaceutical companies in China. According to the prospectus, the overseas subject of the application for listing is named Hansen Pharmaceutical Group Co., Ltd. (Henson Pharmaceuticals), through which the overseas entity controls 100% of the domestic operating entity Jiangsu Hausen Group. Henson Pharmaceuticals currently values HK$65 billion (approximately RMB5 55 billion)
Haussen Pharmaceuticals product line is distributed in six areas: anti-tumor, psychosis, endocrine, digestive tract, anti-infection and cardiovascular, with more than 40 products. In 2017, for example, these six sectors account for 62.1% of China's total drug sales.
the financial situation of the prospectus
financial data show that from 2016 to 2018, Howson Pharmaceuticals' revenue was RMB5.433 billion, RMB6.185 billion and RMB 7.722 billion, respectively;
Haussen Pharmaceuticals Core Products
According to the prospectus, Howson Pharmaceuticals currently has eight market-leading core products and five major products with strong growth potential. According to Frostand s Sullivan, Howson Pharmaceuticals is currently the largest pharmaceutical company in the country with a market share of 9.1 percent, with Olainandin and ameenin with growth potential.
and anti-tumor product line, Howson Pharmaceuticals is mainly in the treatment of high incidence of solid tumors and relatively limited treatment options of blood tumors, is China's fourth largest anti-tumor pharmaceutical company, the market share is currently 2.5%. Includes five major products, the core products of Pryor, Zephy, Wei, Wei Mei, as well as the main products with strong growth potential.
2017 data show howsen Pharmaceuticals ranks fourth in the domestic multi-drug Gram-positive bacterial antibiotic market, with a market share of 11.7%. Including four major products, the core productzen, as well as with strong growth potential of the main products Ofinda, Hengjie, Hengsen.
for the next two years of product layout, Howson Pharmaceuticals will launch nearly 30 drugs in the research between 2019 and 2020, including 15 drugs in the research with high growth potential (including 4 innovative drugs in new molecular entities 1.1 and 8 potential genericdrugs).
for the Haussen listing, industry insiders estimate that after the listing may reach a market value of 100 billion.
Haussen Pharmaceuticals 2019-2020 to launch four new class 1 1 new drugs:
(1) new type 2 diabetes: polyglycol lsenapeptide (GLP-1 receptor agonis)
polyglycol cesena peptide is Haussen's independent research and development of long-acting GLP-1 preparations for the treatment of type 2 diabetes, only once a week injection to achieve long-acting treatment, the domestic market can achieve long-term gl.
(2) "Upgraded Greve": Mfosulfoatinib, used for the treatment of chronic granulocytic leukemia
Msosulfluefluemartini is the first reported second-generation Bcr-Abl tyrosine kinase inhibitor (TKI), structurally, the drug after optimization of Novanilotini molecular structure, the effect is stronger than the meldonium acid Imanibini, but the effect is significantly more than the pancreas.
(3) New hepatitis B: HS-10234
. HS-10234 is a new generation of monophosphamide monoesters, a tynofourvir precursor, which is very stable in plasma and therefore provides a new type of noofovir precursor that improves efficacy while reducing toxicity and side effects.
(4) Non-Small Cell Lung Cancer (NSCLC) Third Generation Molecular Targeting Drug: HS-10296
. HS-10296 is the third-generation molecular targeting drug developed by Howson to treat lung cancer. "HS-10296 is twice as active in the body as similar drugs, " said Sun Chang'an, executive vice president of the Haussen Institute of Medicine. It is particularly important because it has a unique molecular structure and has a unique metabolic pathway that can well avoid adverse reactions such as severe rashes and gastrointestinal toxicity. "
.